This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cairns, R. Articles by Denko, N. Search for Related Content PubMed PubMed Citation Articles by Cairns, R. Articles by Denko, N. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

---

Subject Review

Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment

Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California

Requests for reprints: Nicholas Denko, Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, CCSR-South, Room 1245, Stanford, CA 94305-5152. Phone: 650-724-5066; Fax: 650-723-7382. E-mail: ndenko{at}stanford.edu

Abstract

It is widely recognized that the vasculature of the tumor is inadequate to meet the demands of the growing mass. The malformed vasculature is at least in part responsible for regions of the tumor that are hypoxic, acidotic, and exposed to increased interstitial fluid pressure. These unique aspects of the tumor microenvironment have been shown to act as barriers to conventional chemotherapy or radiation-based therapies. It now seems that while the vasculature initiates these tumor-specific conditions, the cells within the tumor respond to these stresses and add to the unique solid tumor physiology. Gene expression changes have been reported in the tumor for vascular endothelial growth factor, carbonic anhydrase IX, and pyruvate dehydrogenase kinase 1. The activity of these gene products then influences the tumor physiology through alterations in vascular permeability and interstitial fluid pressure, extracellular acidosis, and mitochondrial oxygen consumption and hypoxia, respectively. Novel molecular strategies designed to interfere with the activities of these gene products are being devised as ways to overcome the physiologic barriers in the tumor to standard anticancer therapies. (Mol Cancer Res 2006;4(2):61–70)

This article has been cited by other articles:

				M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF]

				P. V. Dickson, J. B. Hamner, T. L. Sims, C. H. Fraga, C. Y.C. Ng, S. Rajasekeran, N. L. Hagedorn, M. B. McCarville, C. F. Stewart, and A. M. Davidoff Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy Clin. Cancer Res., July 1, 2007; 13(13): 3942 - 3950. [Abstract] [Full Text] [PDF]

				R. A. Cairns, I. Papandreou, P. D. Sutphin, and N. C. Denko Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy PNAS, May 29, 2007; 104(22): 9445 - 9450. [Abstract] [Full Text] [PDF]

				O. A. Andreev, A. D. Dupuy, M. Segala, S. Sandugu, D. A. Serra, C. O. Chichester, D. M. Engelman, and Y. K. Reshetnyak Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo PNAS, May 8, 2007; 104(19): 7893 - 7898. [Abstract] [Full Text] [PDF]

				Y. Zhang, L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B.-s. Jang, N. Le, M. Ho, and I. Pastan Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice Clin. Cancer Res., August 1, 2006; 12(15): 4695 - 4701. [Abstract] [Full Text] [PDF]